bemiparin Indications/Contra | FAERs-F | FAERs-M | Orange Bk | BioActivity |

Stem definitionDrug idCAS RN
heparin derivatives including low molecular mass heparins 4840 9041-08-1

Description:

MoleculeDescription

Synonyms:

  • tinzaparin
  • ardeparin sodium
  • dalteparin sodium
  • tinzaparin sodium
  • bemiparin
  • bemiparin sodium
A low-molecular-weight fragment of heparin, prepared by nitrous acid depolymerization of porcine mucosal heparin. The mean molecular weight is 4000-6000 daltons. It is used therapeutically as an antithrombotic agent. (From Merck Index, 11th ed)
  • Molecular weight:
  • Formula: None
  • CLOGP:
  • LIPINSKI: None
  • HAC: None
  • HDO: None
  • TPSA:
  • ALOGS:
  • ROTB: None

Drug dosage:

DoseUnitRoute
3.50 TU P
2.50 TU P

ADMET properties:

None

Approvals:

DateAgencyCompanyOrphan
Dec. 22, 1994 FDA PFIZER INC

FDA Adverse Event Reporting System (Female)

MedDRA adverse event termLikelihood ratioLikelihood ratio thresholdPatients taking drug having adverse eventPatients taking drug not having adverse eventPatients not taking drug having adverse eventPatients not taking drug not having adverse event
Pulmonary embolism 219.81 12.72 259 21057 108326 46556420
Hepatocellular injury 124.22 12.72 105 21211 29417 46635329
Toxic epidermal necrolysis 107.89 12.72 86 21230 22192 46642554
Drug ineffective 103.38 12.72 95 21221 677743 45987003
Acute kidney injury 96.91 12.72 281 21035 235574 46429172
General physical health deterioration 95.04 12.72 181 21135 115588 46549158
Heparin-induced thrombocytopenia 88.57 12.72 42 21274 4267 46660479
Thrombocytopenia 88.42 12.72 185 21131 126396 46538350
Deep vein thrombosis 74.60 12.72 132 21184 79641 46585105
Rheumatoid arthritis 73.61 12.72 11 21305 240204 46424542
Neutropenic sepsis 62.72 12.72 49 21267 12275 46652471
Cholestasis 59.04 12.72 67 21249 26826 46637920
Arthralgia 55.45 12.72 51 21265 364552 46300194
Product dose omission issue 53.28 12.72 7 21309 168513 46496233
Blood creatine increased 51.95 12.72 30 21286 4560 46660186
Anaemia 47.15 12.72 236 21080 255543 46409203
Neutropenia 45.23 12.72 156 21160 143048 46521698
Vessel puncture site bruise 44.68 12.72 13 21303 328 46664418
Rash maculo-papular 44.27 12.72 59 21257 27815 46636931
Malignant neoplasm progression 44.22 12.72 94 21222 64832 46599914
Agranulocytosis 43.23 12.72 52 21264 22133 46642613
Melaena 42.91 12.72 58 21258 27714 46637032
Arteriovenous fistula occlusion 40.72 12.72 12 21304 317 46664429
Venous pressure jugular decreased 40.68 12.72 8 21308 32 46664714
Febrile neutropenia 39.93 12.72 114 21202 94513 46570233
Blue toe syndrome 39.82 12.72 12 21304 343 46664403
Ovarian hyperstimulation syndrome 39.18 12.72 22 21294 3170 46661576
Pituitary tumour 39.14 12.72 15 21301 900 46663846
Adrenal suppression 38.57 12.72 15 21301 936 46663810
Drug intolerance 38.18 12.72 10 21306 147039 46517707
Hypothalamo-pituitary disorder 35.86 12.72 13 21303 667 46664079
Drug reaction with eosinophilia and systemic symptoms 35.82 12.72 55 21261 29493 46635253
Thrombosis 35.69 12.72 79 21237 55990 46608756
Gamma-glutamyltransferase increased 35.59 12.72 57 21259 31683 46633063
Headache 35.35 12.72 107 21209 478245 46186501
Haemoglobin decreased 35.21 12.72 134 21182 128815 46535931
Drug hypersensitivity 34.82 12.72 36 21280 243789 46420957
Perforation 34.56 12.72 14 21302 973 46663773
Pancytopenia 34.46 12.72 101 21215 84957 46579789
Blood loss anaemia 33.05 12.72 29 21287 8528 46656218
Depression 32.00 12.72 19 21297 170085 46494661
Abdominal wall haemorrhage 30.59 12.72 8 21308 134 46664612
Haematoma 30.09 12.72 53 21263 31819 46632927
Sinusitis 29.78 12.72 11 21305 129757 46534989
Feeling abnormal 29.73 12.72 10 21306 125050 46539696
Pneumothorax traumatic 29.64 12.72 8 21308 152 46664594
Cerebral haemorrhage 27.85 12.72 48 21268 28323 46636423
Abdominal wall haematoma 27.83 12.72 17 21299 2864 46661882
Dermatitis exfoliative 27.52 12.72 22 21294 5694 46659052
Blood creatinine increased 27.46 12.72 87 21229 76316 46588430
Hyperkalaemia 27.39 12.72 67 21249 50642 46614104
Jaundice 27.28 12.72 48 21268 28797 46635949
Cardiomyopathy acute 27.20 12.72 8 21308 210 46664536
Pyrexia 26.94 12.72 260 21056 348542 46316204
Biliary sepsis 26.77 12.72 10 21306 559 46664187
Gastric antral vascular ectasia 26.55 12.72 10 21306 572 46664174
Catheter site thrombosis 26.40 12.72 7 21309 124 46664622
Psychiatric decompensation 26.35 12.72 12 21304 1111 46663635
Activated partial thromboplastin time prolonged 25.91 12.72 23 21293 6866 46657880
Intra-abdominal haemorrhage 25.76 12.72 15 21301 2315 46662431
Hyperthyroidism 25.39 12.72 29 21287 11682 46653064
Bronchopulmonary dysplasia 25.36 12.72 8 21308 267 46664479
Cardiac failure 25.12 12.72 87 21229 79861 46584885
Haemorrhagic erosive gastritis 25.00 12.72 8 21308 280 46664466
Bone marrow eosinophilic leukocyte count increased 24.86 12.72 5 21311 23 46664723
Therapeutic product effect decreased 24.77 12.72 4 21312 82597 46582149
Exposure during pregnancy 24.40 12.72 106 21210 108106 46556640
Allergic hepatitis 23.89 12.72 5 21311 29 46664717
Drug interaction 23.52 12.72 166 21150 202928 46461818
Arthropathy 23.47 12.72 5 21311 84695 46580051
Muscle haemorrhage 23.30 12.72 16 21300 3288 46661458
Ascites 22.66 12.72 51 21265 36533 46628213
Phlebitis 22.43 12.72 20 21296 6006 46658740
Premature baby 22.35 12.72 34 21282 18078 46646668
Gastrointestinal haemorrhage 21.59 12.72 81 21235 77292 46587454
Femoral neck fracture 20.93 12.72 22 21294 8081 46656665
Pleural effusion 20.83 12.72 84 21232 82868 46581878
Abdominal discomfort 20.79 12.72 23 21293 151142 46513604
Hepatitis cholestatic 20.68 12.72 20 21296 6657 46658089
Cardiac failure congestive 20.67 12.72 8 21308 91742 46573004
Pain 20.37 12.72 131 21185 476817 46187929
Caesarean section 20.25 12.72 31 21285 16572 46648174
Granulomatous liver disease 19.93 12.72 9 21307 817 46663929
Neoplasm progression 19.76 12.72 40 21276 26643 46638103
Renal tubular acidosis 19.67 12.72 11 21305 1572 46663174
Intra-abdominal haematoma 19.37 12.72 11 21305 1620 46663126
Cholestatic liver injury 19.34 12.72 12 21304 2078 46662668
Foetal growth restriction 19.09 12.72 19 21297 6548 46658198
Joint swelling 19.00 12.72 29 21287 166044 46498702
Haematoma muscle 18.92 12.72 8 21308 620 46664126
Retroperitoneal haemorrhage 18.73 12.72 13 21303 2717 46662029
Diarrhoea haemorrhagic 18.71 12.72 20 21296 7489 46657257
Sepsis 18.65 12.72 116 21200 135898 46528848
Musculoskeletal stiffness 18.34 12.72 11 21305 97982 46566764
Fatigue 18.25 12.72 184 21132 608513 46056233
Limbal swelling 18.11 12.72 4 21312 31 46664715
Electrolyte imbalance 18.04 12.72 30 21286 17196 46647550
Anaemia folate deficiency 17.77 12.72 6 21310 249 46664497
Multiple organ dysfunction syndrome 17.77 12.72 58 21258 51652 46613094
Epistaxis 17.67 12.72 67 21249 64238 46600508
Gastric ulcer 17.67 12.72 34 21282 21829 46642917
Cerebral infarction 17.26 12.72 35 21281 23331 46641415
Alanine aminotransferase increased 17.22 12.72 83 21233 88368 46576378
Lordosis 17.04 12.72 6 21310 283 46664463
Protein C decreased 16.85 12.72 4 21312 44 46664702
Respiratory disorder 16.84 12.72 38 21278 27262 46637484
Treatment failure 16.66 12.72 11 21305 93076 46571670
Haemolysis 16.64 12.72 17 21299 6042 46658704
Acute generalised exanthematous pustulosis 16.63 12.72 21 21295 9384 46655362
Faecaloma 16.47 12.72 19 21297 7733 46657013
Pneumobilia 16.20 12.72 5 21311 155 46664591
Asthma 16.14 12.72 11 21305 91531 46573215
Maternal drugs affecting foetus 16.10 12.72 16 21300 5502 46659244
Gastrointestinal tract adenoma 16.08 12.72 6 21310 334 46664412
Varices oesophageal 16.08 12.72 12 21304 2807 46661939
Constipation 16.07 12.72 135 21181 173962 46490784
Blood alkaline phosphatase increased 15.99 12.72 47 21269 39562 46625184
Visual acuity reduced transiently 15.96 12.72 5 21311 163 46664583
Protein S decreased 15.96 12.72 4 21312 56 46664690
Hyperlipasaemia 15.92 12.72 7 21309 597 46664149
Toxicity to various agents 15.84 12.72 47 21269 211719 46453027
Infantile haemangioma 15.83 12.72 4 21312 58 46664688
Therapeutic product effect incomplete 15.74 12.72 8 21308 78145 46586601
Intracranial pressure increased 15.70 12.72 14 21302 4206 46660540
Cerebellar haematoma 15.53 12.72 6 21310 368 46664378
Mucosal inflammation 15.50 12.72 46 21270 38930 46625816
Chemotherapeutic drug level increased 15.49 12.72 5 21311 180 46664566
Needle issue 15.42 12.72 16 21300 5788 46658958
Acidosis 15.26 12.72 22 21294 11152 46653594
Gait disturbance 15.10 12.72 27 21289 145236 46519510
Thrombophlebitis 15.09 12.72 14 21302 4423 46660323
Cardiac hypertrophy 14.95 12.72 8 21308 1049 46663697
Cholecystitis 14.89 12.72 25 21291 14441 46650305
Persecutory delusion 14.85 12.72 11 21305 2544 46662202
International normalised ratio increased 14.70 12.72 51 21265 46832 46617914
Haemoptysis 14.56 12.72 35 21281 26154 46638592
Embolism 14.34 12.72 17 21299 7121 46657625
Subcutaneous haematoma 14.33 12.72 9 21307 1592 46663154
Abdominal pain 14.20 12.72 164 21152 229867 46434879
Hyperhidrosis 14.12 12.72 12 21304 89296 46575450
Vena cava thrombosis 14.07 12.72 10 21306 2169 46662577
Chondrodystrophy 14.06 12.72 4 21312 93 46664653
Haemangioma congenital 13.96 12.72 6 21310 484 46664262
Stevens-Johnson syndrome 13.89 12.72 32 21284 23265 46641481
Foetal growth abnormality 13.85 12.72 3 21313 21 46664725
Bone marrow oedema 13.71 12.72 7 21309 834 46663912
Vascular occlusion 13.61 12.72 7 21309 846 46663900
Engraftment syndrome 13.37 12.72 5 21311 280 46664466
Red cell distribution width increased 13.31 12.72 17 21299 7687 46657059
Eosinophilia 13.27 12.72 28 21288 19189 46645557
Leukopenia 13.20 12.72 64 21252 68279 46596467
Post procedural haematoma 13.12 12.72 8 21308 1343 46663403
Injection site erythema 13.04 12.72 9 21307 74418 46590328
Injection site pain 12.95 12.72 18 21298 107134 46557612
Alopecia 12.91 12.72 35 21281 162379 46502367
Application site haemorrhage 12.88 12.72 7 21309 947 46663799
Loss of personal independence in daily activities 12.86 12.72 5 21311 57178 46607568
Alveolitis 12.80 12.72 10 21306 2503 46662243
Erythema 12.77 12.72 110 21206 142710 46522036
Osteochondrosis 12.77 12.72 7 21309 963 46663783

FDA Adverse Event Reporting System (Male)

MedDRA adverse event termLikelihood ratioLikelihood ratio thresholdPatients taking drug having adverse eventPatients taking drug not having adverse eventPatients not taking drug having adverse eventPatients not taking drug not having adverse event
Pulmonary embolism 116.43 12.88 189 18493 77946 29855850
Hepatocellular injury 85.62 12.88 92 18590 25379 29908417
Drug ineffective 75.85 12.88 61 18621 340326 29593470
General physical health deterioration 72.52 12.88 179 18503 99765 29834031
Thrombocytopenia 64.66 12.88 210 18472 136834 29796962
Acute kidney injury 62.88 12.88 336 18346 273506 29660290
Heparin-induced thrombocytopenia 57.59 12.88 38 18644 5345 29928451
Lymph node calcification 51.67 12.88 14 18668 194 29933602
Appendicolith 51.63 12.88 20 18662 899 29932897
Toxic epidermal necrolysis 48.69 12.88 58 18624 17882 29915914
Neutropenia 47.66 12.88 182 18500 128358 29805438
Toxicity to various agents 37.79 12.88 33 18649 177150 29756646
Pulmonary sarcoidosis 37.41 12.88 14 18668 572 29933224
Deep vein thrombosis 37.27 12.88 102 18580 60399 29873397
Drug abuse 37.05 12.88 4 18678 82068 29851728
Sepsis 36.47 12.88 184 18498 146211 29787585
Aplasia 34.92 12.88 25 18657 4012 29929784
Haemorrhage 31.74 12.88 81 18601 45998 29887798
Mucosal inflammation 31.52 12.88 63 18619 30431 29903365
Bronchial disorder 31.39 12.88 14 18668 900 29932896
Suspected product quality issue 30.87 12.88 9 18673 165 29933631
Muscle haemorrhage 29.91 12.88 22 18660 3681 29930115
Hepatic haematoma 28.77 12.88 11 18671 477 29933319
Peritoneal haematoma 28.59 12.88 7 18675 63 29933733
Haematemesis 28.13 12.88 55 18627 26148 29907648
Bronchial obstruction 27.79 12.88 15 18667 1461 29932335
Pancytopenia 27.13 12.88 115 18567 84937 29848859
Chondrocalcinosis 27.01 12.88 9 18673 260 29933536
Floppy infant 26.61 12.88 7 18675 86 29933710
Death 26.42 12.88 124 18558 357159 29576637
Septic shock 25.98 12.88 93 18589 63514 29870282
Hyperkalaemia 25.68 12.88 95 18587 65915 29867881
Compartment syndrome 25.01 12.88 17 18665 2510 29931286
Genitalia external ambiguous 23.92 12.88 8 18674 234 29933562
Lung cancer metastatic 22.66 12.88 16 18666 2512 29931284
Febrile neutropenia 22.38 12.88 128 18554 106565 29827231
Rash maculo-papular 22.18 12.88 49 18633 25369 29908427
Congenital bladder anomaly 22.08 12.88 8 18674 298 29933498
Haematoma 21.84 12.88 47 18635 23906 29909890
Abdominal pain 21.78 12.88 152 18530 135502 29798294
Mucosal disorder 21.62 12.88 13 18669 1554 29932242
Klebsiella infection 21.60 12.88 24 18658 6863 29926933
Embolism 21.25 12.88 24 18658 6985 29926811
Respiratory tract infection 21.01 12.88 36 18646 15470 29918326
Product dose omission issue 20.83 12.88 16 18666 91615 29842181
Cholestasis 20.54 12.88 47 18635 24903 29908893
Thrombocytosis 20.46 12.88 17 18665 3396 29930400
Foetal hypokinesia 20.45 12.88 8 18674 369 29933427
Haemorrhagic disorder 20.37 12.88 9 18673 566 29933230
Malignant neoplasm progression 20.21 12.88 94 18588 72193 29861603
Full blood count abnormal 20.21 12.88 11 18671 1089 29932707
Hypokalaemia 20.16 12.88 73 18609 50119 29883677
Cardiac failure congestive 20.14 12.88 14 18668 84393 29849403
Coagulation factor VII level decreased 20.09 12.88 6 18676 120 29933676
Product communication issue 19.95 12.88 5 18677 50 29933746
Respiratory disorder neonatal 19.42 12.88 11 18671 1177 29932619
Neonatal respiratory depression 19.38 12.88 8 18674 425 29933371
Pulmonary artery thrombosis 19.18 12.88 9 18673 651 29933145
Prothrombin time shortened 19.16 12.88 12 18670 1543 29932253
Depression 19.06 12.88 17 18665 90420 29843376
Haemolytic anaemia 18.79 12.88 27 18655 9983 29923813
Dizziness 18.60 12.88 61 18621 194848 29738948
Appendicitis 18.56 12.88 21 18661 6123 29927673
Reading disorder 18.39 12.88 7 18675 300 29933496
Jaundice cholestatic 18.09 12.88 18 18664 4533 29929263
Hypertrophic osteoarthropathy 17.50 12.88 5 18677 85 29933711
Butterfly rash 17.08 12.88 5 18677 93 29933703
Wrong strength 16.60 12.88 5 18677 103 29933693
Eosinophil percentage decreased 16.42 12.88 5 18677 107 29933689
Cardiac flutter 16.24 12.88 11 18671 1615 29932181
Miosis 16.12 12.88 22 18660 7754 29926042
Hepatitis cholestatic 15.91 12.88 22 18660 7850 29925946
Drug hypersensitivity 15.52 12.88 12 18670 68507 29865289
Therapeutic product effect prolonged 15.27 12.88 6 18676 280 29933516
Cardiogenic shock 15.27 12.88 33 18649 16828 29916968
Abdominal sepsis 15.19 12.88 9 18673 1048 29932748
Leukopenia 14.94 12.88 72 18610 56087 29877709
Large intestine perforation 14.90 12.88 21 18661 7630 29926166
Insomnia 14.84 12.88 22 18660 93314 29840482
Gamma-glutamyltransferase increased 14.71 12.88 46 18636 29304 29904492
Lung disorder 14.57 12.88 48 18634 31421 29902375
Lymphopenia 14.57 12.88 28 18654 13135 29920661
Agranulocytosis 14.51 12.88 38 18644 21904 29911892
Anxiety 14.47 12.88 21 18661 89850 29843946
Engraftment syndrome 14.40 12.88 8 18674 825 29932971
Portal vein thrombosis 14.33 12.88 14 18668 3450 29930346
Cerebral haemorrhage 14.20 12.88 49 18633 32838 29900958
Pyrexia 14.19 12.88 260 18422 294229 29639567
Myositis 13.93 12.88 24 18658 10353 29923443
Metastatic malignant melanoma 13.86 12.88 11 18671 2059 29931737
Penile necrosis 13.84 12.88 4 18678 71 29933725
Neoplasm progression 13.79 12.88 33 18649 17990 29915806
Soft tissue sarcoma 13.69 12.88 4 18678 74 29933722
Phlebitis 13.32 12.88 14 18668 3761 29930035
Bicytopenia 13.18 12.88 10 18672 1752 29932044
IIIrd nerve disorder 13.08 12.88 4 18678 87 29933709
Gastrointestinal stoma output increased 13.04 12.88 3 18679 20 29933776
Foetal exposure during delivery 13.04 12.88 4 18678 88 29933708
Blood pressure diastolic increased 13.03 12.88 12 18670 2746 29931050
Bladder tamponade 12.90 12.88 6 18676 425 29933371

Pharmacologic Action:

SourceCodeDescription
ATC B01AB10 BLOOD AND BLOOD FORMING ORGANS
ANTITHROMBOTIC AGENTS
ANTITHROMBOTIC AGENTS
Heparin group
ATC B01AB12 BLOOD AND BLOOD FORMING ORGANS
ANTITHROMBOTIC AGENTS
ANTITHROMBOTIC AGENTS
Heparin group
FDA CS M0010191 Heparin, Low-Molecular-Weight
FDA EPC N0000175586 Low Molecular Weight Heparin
MeSH PA D000925 Anticoagulants
MeSH PA D002317 Cardiovascular Agents
MeSH PA D005343 Fibrinolytic Agents
MeSH PA D006401 Hematologic Agents
CHEBI has role CHEBI:50249 anticoagulante

Drug Use (View source of the data)

DiseaseRelationSNOMED_IDDOID
Pulmonary embolism indication 59282003 DOID:9477
Deep venous thrombosis indication 128053003

Acid dissociation constants calculated using MoKa v3.0.0

None

Orange Book patent data (new drug applications)

None

Orange Book exclusivity data (new drug applications)

Formulation strengthTrade nameApplicantApplication numberApproval dateTypeDose formRouteExclusivity dateDescription
10,000IU/0.4ML (25,000IU/ML) FRAGMIN PFIZER N020287 May 1, 2007 DISCN INJECTABLE SUBCUTANEOUS May 16, 2022 NEW PATIENT POPULATION
10,000IU/ML (10,000IU/ML) FRAGMIN PFIZER N020287 Jan. 30, 1998 RX INJECTABLE SUBCUTANEOUS May 16, 2022 NEW PATIENT POPULATION
12,500IU/0.5ML (25,000IU/ML) FRAGMIN PFIZER N020287 May 1, 2007 RX INJECTABLE SUBCUTANEOUS May 16, 2022 NEW PATIENT POPULATION
15,000IU/0.6ML (25,000IU/ML) FRAGMIN PFIZER N020287 May 1, 2007 RX INJECTABLE SUBCUTANEOUS May 16, 2022 NEW PATIENT POPULATION
18,000IU/0.72ML (25,000IU/ML) FRAGMIN PFIZER N020287 May 1, 2007 RX INJECTABLE SUBCUTANEOUS May 16, 2022 NEW PATIENT POPULATION
2,500IU/0.2ML (12,500IU/ML) FRAGMIN PFIZER N020287 Dec. 22, 1994 RX INJECTABLE SUBCUTANEOUS May 16, 2022 NEW PATIENT POPULATION
5,000IU/0.2ML (25,000IU/ML) FRAGMIN PFIZER N020287 March 18, 1996 RX INJECTABLE SUBCUTANEOUS May 16, 2022 NEW PATIENT POPULATION
7,500 IU/0.75ML FRAGMIN PFIZER N020287 April 4, 2002 DISCN INJECTABLE INJECTION May 16, 2022 NEW PATIENT POPULATION
7,500IU/0.3ML (25,000IU/ML) FRAGMIN PFIZER N020287 April 4, 2002 RX INJECTABLE SUBCUTANEOUS May 16, 2022 NEW PATIENT POPULATION
95,000IU/3.8ML (25,000IU/ML) FRAGMIN PFIZER N020287 April 4, 2002 RX INJECTABLE SUBCUTANEOUS May 16, 2022 NEW PATIENT POPULATION
95,000IU/9.5ML (10,000IU/ML) FRAGMIN PFIZER N020287 April 4, 2002 DISCN INJECTABLE SUBCUTANEOUS May 16, 2022 NEW PATIENT POPULATION

Bioactivity Summary:

None

External reference:

IDSource
N3927D01PB UNII
9005-49-6 SECONDARY_CAS_RN
4020894 VANDF
4021054 VANDF
4021237 VANDF
4024199 VANDF
C0297268 UMLSCUI
CHEBI:28304 CHEBI
CHEMBL1201448 ChEMBL_ID
CHEMBL3707365 ChEMBL_ID
CHEMBL2108806 ChEMBL_ID
CHEMBL1201460 ChEMBL_ID
DB09258 DRUGBANK_ID
CHEMBL1201414 ChEMBL_ID
6985 INN_ID
7501 INN_ID
D017985 MESH_DESCRIPTOR_UI
D000078222 MESH_DESCRIPTOR_UI
C093450 MESH_SUPPLEMENTAL_RECORD_UI
C411345 MESH_SUPPLEMENTAL_RECORD_UI
772 PUBCHEM_CID
5688 INN_ID
6764 INN_ID
DB06822 DRUGBANK_ID
6846 IUPHAR_LIGAND_ID
104466 RXNORM
15471 MMSL
4531 MMSL
d04659 MMSL
005078 NDDF
007911 NDDF
008338 NDDF
108987000 SNOMEDCT_US
108990006 SNOMEDCT_US
350469004 SNOMEDCT_US
395908006 SNOMEDCT_US
410964003 SNOMEDCT_US
410965002 SNOMEDCT_US
410967005 SNOMEDCT_US
412608008 SNOMEDCT_US

Pharmaceutical products:

ProductCategoryIngredientsNDCFormQuantityRouteMarketingLabel
Fragmin HUMAN PRESCRIPTION DRUG LABEL 1 0069-0195 INJECTION 2500 [iU] SUBCUTANEOUS NDA 28 sections
Fragmin HUMAN PRESCRIPTION DRUG LABEL 1 0069-0196 INJECTION 5000 [iU] SUBCUTANEOUS NDA 28 sections
Fragmin HUMAN PRESCRIPTION DRUG LABEL 1 0069-0206 INJECTION 7500 [iU] SUBCUTANEOUS NDA 28 sections
Fragmin HUMAN PRESCRIPTION DRUG LABEL 1 0069-0217 INJECTION 10000 [iU] SUBCUTANEOUS NDA 28 sections
Fragmin HUMAN PRESCRIPTION DRUG LABEL 1 0069-0220 INJECTION 12500 [iU] SUBCUTANEOUS NDA 28 sections
Fragmin HUMAN PRESCRIPTION DRUG LABEL 1 0069-0223 INJECTION 15000 [iU] SUBCUTANEOUS NDA 28 sections
Fragmin HUMAN PRESCRIPTION DRUG LABEL 1 0069-0228 INJECTION 18000 [iU] SUBCUTANEOUS NDA 28 sections
Fragmin HUMAN PRESCRIPTION DRUG LABEL 1 0069-0232 INJECTION 25000 [iU] SUBCUTANEOUS NDA 28 sections